Background: Matrix metalloproteinases (MMPs) are zinc-or calcium-dependent
through activation of signal transduction pathways. When their balance is disrupted, MMPs become initiators of extracellular matrix destruction and exacerbate local and systemic diseases, such as rheumatoid arthritis, atherosclerosis, and periodontal disease. 1, 2 Multiple cell types in both healthy and periodontally diseased tissues are capable of expressing MMPs. 5, 6 These cell types include gingival sulcular epithelial cells, gingival fibroblasts, endothelial cells, monocytes, macrophages, plasma cells, neoplastic cells, and polymorphonuclear (PMN) leukocytes. MMPs also play a major role in the development and progression of chronic periodontitis by breaking down and destroying collagen, the major substrate of gingival and periodontal connective tissues and bone matrix. 7 Elevated concentrations of various MMPs have been detected in gingival crevicular fluid around teeth displaying periodontitis. [7] [8] [9] Recently, we found that human beta defensin 3 (HBD3), a cationic antimicrobial peptide, and histatin 5 regulate chemokine and proinflammatory cytokine responses in dendritic cells exposed to Porphyromonas gingivalis hemagglutinin B (HagB). 10, 11 HagB is a major virulence factor of P. gingivalis involved in non-fimbrial adhesion of the microorganism to host cells. It is a 49.0 kDa protein composed of 350 amino acid residues with a pI of 8. 42 . Recombinant HagB induces a robust chemokine and cytokine response in dendritic cells. 10, 11 HBD3 is a dynamic host defense peptide produced by a variety of cells and tissues of the oral cavity. 12, 13 It is a small, 45 amino acid residue molecule with a strong cationic charge (+11) and monoisotopic mass of 5,157.7 Da. 14 It has a strong role in innate and adaptive immunity. 15 HBD3 kills microorganisms; 13, 14, 16, 17 enhances the barrier function of mucosa by regulating permeability and membranetight junctions in keratinocytes; 18 chemoattracts monocytes, macrophages, T cells, neutrophils, immature dendritic cells, and mast cells; promotes differentiation of human mesenchymal stem cells and osteoblasts; 19 and regulates complement activation. 20, 21 Important to this application, HBD3 can also modulate biomarker responses. We have demonstrated that HBD3 (at low concentrations) attenuates proinflammatory agonist-induced chemokine and proinflammatory cytokine responses of dendritic cells. HBD3 (at high concentrations) enhances agonist-induced chemokine and proinflammatory cytokine responses of dendritic cells. 10, 11 We used a computational and experimental modeling approach to show that the biomarker responses were strongly influenced by the concentration and timing of HBD3 or histatin 5 treatment. We also found that dendritic cells exposed to HagB produce MMPs. 10 Here, it is confirmed that HagB induces the production of MMPs in dendritic cells and shown that HagB-induced MMP responses were lower when HagB was mixed with HBD3 in dendritic cell cultures.
MATERIALS AND METHODS

Solutions
HagB was prepared as previously described in a number of studies. 10, 11, 22, 23 HBD3 was purchased commercially * . 0.01 M phosphate-buffered saline (PBS) with 0.14 M NaCl, pH 7.2, was prepared and used as a control solution and diluent to prepare 0.2 M HagB, 0.2 M HBD3, and 2.0 M HBD3 solutions. All solutions were closely monitored for endotoxin content. † PBS contained 4.0 pg endotoxin/mL (n = 3), reconstituted HBD3 solution contained 0.07 pg endotoxin/ g peptide (n = 3), and HagB contained 14.0 pg endotoxin/ g protein (n = 3).
Dendritic cells
Dendritic cells were obtained from multiple sources. In replication 1, dendritic cells were prepared from primary peripheral human blood monocytes. ‡ In replications 2 and 3, dendritic cells were obtained from different individuals. § Cells in the latter preparations were of myeloid origin and stained 31.5% CD1c + /79.1% CD11c + and 54.4% CD141 + /79.1% CD11c + . ¶ Dendritic cells were cultivated in Lymphocyte Growth Media-3 (LGM)-3.
Experimental design
In each of three replications, 0.8 mL of 1.0 × 10 5 viable dendritic cells in LGM-3 were added to 24-well plates # at a density of 4.1 × 10 4 cells/cm 2 . After 2 hours, LGM-3 medium containing non-adherent cells and debris was removed and 0.9 mL of LGM-3 was added back. 0.1 mL test and control solutions were added to adhered cells. Thus, dendritic cells were exposed to ( In prior work 10 it was observed that P. gingivalis HagB induced robust chemokine and cytokine responses in dendritic cells in 16 hours, and these HagB-induced responses could be altered by adding HBD3 to the dendritic cell cultures. That time period was used in this study. At 16 hours, cell culture supernatants were removed and centrifuged at 13,200 × g (16,100 rpm) at 25 • C for 5 minutes to pellet non-adherent cells and cell debris. Supernatants were removed and frozen at −80 • C.
Viability
It has recently been found that high concentrations of HBD3 can be cytotoxic for dendritic cells. 24 To ensure that changes in MMP concentrations were not due to cytotoxic effects of treatment solutions on dendritic cells, their viability was monitored in each replication. The cytotoxic effects of PBS, HagB, HBD3, and HagB + HBD3 mixtures on dendritic cells were determined by measuring the median fluorescence intensity (MFI) of the metabolic conversion of resazurin * to resorufin as previously described. 24 The percent viability was determined as the (MFI of test solution/MFI of PBS [Group 1] solution) × 100.
Determination of MMPs
Concentrations (pg/mL) of MMP1, MMP2, MMP7, MMP9, and MMP12 were determined in dendritic cell culture media supernatants in triplicate from each of the three replications with commercial multiplexed fluorescent beadbased immunoassays † in the particle counter ‡ as previously described in detail. 10, 11, 23 Standard curves ranged from 5.0 to 20,000.0 pg/mL (MMP1), 12.0 to 50,000.0 pg/mL (MMP2), 98.0 to 400,000.0 pg/mL (MMP7), 2.4 to 10,000.0 pg/mL (MMP9), and 24.0 to 100,000.0 pg/mL (MMP12).
Modeled HBD3 effects on HagB-induced MMP responses
An integrated cell network was used to create a predictive computational simulation model of human dendritic cells as previously described. 10, 11 This model was used to predict the effect of HBD3 on the HagB-induced MMP responses of dendritic cells. This model provides a dynamic and transparent view of dendritic cell physiology at the functional proteomics abstraction level and predicts outcomes for different experimental scenarios in an automated high-throughput system. The model was manually aggregated, and is currently updated, from published research and collaborative data on signaling pathways, intermediates, transcription factors, enzyme kinetics, and gene regulations comprising 3,860 biologic species with more than 15,433 cross-talk interactions. The technology has been recently used to predict: 1) elastintriggered transient proinflammatory responses by human dermal fibroblasts; 25 2) anti-aggregation of alpha-synuclein in M17 dopaminergic cells; 26 ATPase activity of heat shock protein 90 in tumor cells, endothelial cells, and stromal * Alamar Blue, Invitrogen Corp., Carlsbad, CA. † EMD Millipore, Billerica, MA. ‡ Luminex 100 IS Instrument, Luminex, Austin, TX. cells; 27 3) effects of progesterone and cyclooxygenase-2 (Cox2) inhibitors on progesterone receptor isoforms A and B in myometrial cells; 28 4) butein inhibition of signal transducer and activator of transcription 3 (STAT3) expression in cell line HepG2, cell line SNU-387, and cell line PLC/PRF5 human hepatocellular carcinoma cells; 29 and 5) effects of isorhamnetin on the peroxisome proliferator-activated receptor gamma signaling cascade. 30 It has also been used to predict the programmed death ligand 1 (PD-L1) expression on oral squamous cell carcinoma cells. 31, 32 The predictive computational simulation model of the effects of HBD3 and histatin 5 on HagB-induced chemokines and cytokines in dendritic cells was extensively validated in the prior studies by Harvey et al 10 and Borgwardt et al., 11 respectively. The dendritic cell network was used to predict the HagB-induced signaling pathways in dendritic cells leading to the production of MMPs and influencing effects of HBD3 on HagB-induced signal transduction.
Statistical analysis
Concentrations of MMPs in dendritic cell culture media supernatants were interpolated from curves constructed from the MMP standards and their respective MFI readings directly on the instrument § and readout files. ¶ Dendritic cells in each of the three replications produced low concentrations of MMPs (Group 1). The responses were unique to the three dendritic cell sources in each replication. HagB (Group 2) induced the production of MMP1, MMP2, MMP7, MMP9, and MMP12 above baseline levels (Group 1). The responses and magnitude of these responses varied among replications for each MMP and the differences of MMP production across replications were normalized. The percent increase was determined as the ([MMP concentration of test groups] -[MMP concentration of control Group 1]/MMP concentration of Group 1) × 100.
An ANOVA was then fit to the HagB-induced percent increase responses, and the effect of HBD3 on HagB-induced MMP responses was determined versus that induced by HagB alone using Dunnett's test. 33 A 0.05 level was used to determine statistically significant differences. All analyses were conducted using a commercial software package. # 
RESULTS
Viability
HagB-induced MMP responses in dendritic cells
Dendritic cells in each replication produced low concentrations of MMP1, −2, −7, −9, and −12 in control cultures exposed to PBS. The responses were unique to dendritic cell sources in each replication. HagB (Group 2) induced the production of MMP1, −2, −7, −9, and −12 above these baseline levels and responses varied among replications. Therefore, the differences of MMP concentrations across replications were normalized to a percent increase of MMP, and the results for three samplings per each of three replications (n = 9) were combined. HagB-induced MMP1 (172.0% ± 51.7% standard error of mean [SEM] increase), MMP2 (118.9% ± 106.8% SEM increase), MMP7 (24.6% ± 14.0% SEM increase), MMP9 (92.7% ± 43.0% SEM increase), and MMP12 (210.6% ± 51.6% SEM increase) responses (Figure 2 ).
Influence of HBD3 on HagB-induced MMP response
The effects of HBD3 on HagB-induced MMP responses were then determined and compared to those induced by HagB alone using the method of Dunnett. Three patterns were observed ( Figures 3A through 3E) . First, 0.2 M HBD3 (Group 4) significantly enhanced the 0.2 M HagB-induced MMP7 response, and 2.0 M HBD3 (Group 6) significantly attenuated 0.2 M HagB-induced MMP7 response (Fig C) . 
Predicted influence of HBD3 on HagB-induced MMP response
In model simulations (Figure 4 ), HagB was predicted to bind to CD14 and activin receptors. 10 In the predicted network schematic, MMPs would be produced via activation of myeloid differentiation primary response 88/tumor necrosis factor receptor associated factor 6 (MyD88/TRAF6) and Src homology 2 domain containing transforming protein 1/extracellular signal-regulated kinase (SHC1/ERK) pathways, respectively. Both activin and CD14 signals converge at the activation of mitogen-activated protein kinases (MAPKs), serine/threonine kinase 1 (AKT), and protein kinase C (PKC) to activate the transcription factors nuclear factor-kappa B (NF-B), activator protein-1 (AP1), specificity protein 1 (SP1), nuclear factor of activated T cells (NFAT), catenin beta 1 (CTNNB1), and hypoxia-inducible factor 1A (HIF1A), which transcribe different MMPs. Previously we found that HBD3 had an inhibitory effect on dendritic cells. 10 It binds to G-protein-coupled receptors chemokine receptor (CCR) 2B and CCR6, stimulates Gq and Gi respectively, and activates the tyrosine protein kinase (LYN)/spleen tyrosine kinase (SYK)/phospholipase C (PLC)/protein kinase c-dystroglycan (PKC-DAG) pathway converging at the activation of AKT, NF-B, and NFAT. HBD3 negatively regulates MMP production by inhibiting 
DISCUSSION
Previously, P. gingivalis HagB was found to be a potent chemokine and cytokine stimulus. 10 HagB-treated dendritic cells produced ∼37 chemokines and cytokines in 16 hours.
In that study, HBD3 was found to alter the HagB-induced chemokine and cytokine response in dendritic cells. 10 In this present study, 2.0 m HagB was found to be an MMP stimulus and HBD3 was found to alter the HagB-induced MMP1, -7, and -9 responses in dendritic cells at 16 hours. The role of HBD3 in regulating MMP responses to specific proinflammatory antigenic exposure is largely unknown, particularly the effects of HBD3 concentration and antigen exposure to dendritic cells. Dendritic cells in this study were from different sources and produced different background levels of MMPs. In replication 1, dendritic cells were prepared from primary peripheral human blood monocytes. In replications 2 and 3, dendritic cells were obtained as commercial preparation. Because of the different background levels of MMPs, we normalized the responses and determined the HagB-induced percent change. This allowed the different replications to be pooled. An ANOVA was then fitted to the HagB-induced percent increase responses and the effect of HBD3 on HagB-induced MMP responses was determined versus that induced by HagB alone using Dunnett's test. 33 Similar to our previous work, 10 HagB did induce MMP1, −2, −7, −9, and −12 responses (Figure 2 ).
Higher concentrations of HBD3 are known to be cytotoxic for dendritic cells. 24 In the present study, inocula containing 0.2 and 2.0 M HBD3 were not cytotoxic for dendritic cell cultures alone or in combination with HagB ( Figure 1 concentration effect of HBD3 on HagB-induced MMP responses in human myeloid dendritic cells was similar to the concentration effect of HBD3 on HagB-induced chemokine and proinflammatory cytokine responses stimulus. 10 HagB and HBD3 influence similar signaling pathways. HagB stimulates dendritic cells in a toll like receptor 4 (TLR4)-dependent manner, and MyD88 and TIR-domaincontaining adapter-inducing interferon-(TRIF) are required for their optimal activation. 34 HBD3 affects the activity of proinflammatory pathways associated with MyD88 and TRIF. 35, 36 Therefore, to determine the parameters of HBD3 influencing the HagB-induced responses seen at 16 hours, a computational simulation dendritic cell model was used to predict MMP signaling pathways.
There are a number of influencing factors on HagBinduced MMP production. For example, activating transcription factor-3 (ATF3) is a negative regulator of TLR signaling in dendritic cells, 37 which can suppress the transcription of MMP2 38, 39 and MMP1, MMP3, and MMP10 expressions. 40 MMP2 did not have much of a response in our study. ATF3 is transcribed by ATF2, which comes downstream to the MAPK pathways. With HagB stimulation, there could be an increase in MAPK activation. Increase in MAPK activation positively influences MMP2 expression in dendritic cells through AP-1, SP-1 and HIF1A but at the same time, it negatively regulates MMP2 expression via ATF3. With HagB stimulation and increased MAPKs, MMP2 is activated as well as inhibited via MAPKs, hence levels of MMP2 may not vary.
There are additional influencing factors on MMP production. p38 negatively regulates MMP1 and MMP13 expression. [41] [42] [43] MMP13 was activated by AP-1 and NF-B in our model. All these transcription factors can be activated by MAPKs (p38, ERK, etc.), which gets activated with HagB stimulation. If we consider the link in dendritic cells where p38 negatively regulates MMP13 expression, then as in the case of MMP2, maybe we can show MMP13 expression not getting changed with HagB stimulation because downstream of p38, we have activation of MMP13 expression via AP-1 and NF-B as well as inhibition of MMP13 expression. To what extent these factors influence the effect of HBD3 on HagBinduced MMP production by dendritic cells will have to be determined using pathway inhibitors.
In prior studies, 10,11 the current authors used HagB as a proinflammatory stimulus to induce chemokine and cytokine responses in human dendritic cells. We demonstrated that HBD3 binds to select sites on HagB, and the interaction among these molecules attenuated or enhanced proinflammatory HagB-induced chemokine and cytokine responses. 10, 11 In this study, we used HagB in similar concentrations to induce MMP1, −2, −7, −9, and −12 responses in human dendritic cells. We observed differing patterns of responses ( Figures 3A through 3E ) similar to HagB-induced chemokine and cytokine responses. 10 Figures 3A and 3D) . Finally, neither concentrations of HBD3 (Group 4, Group 6) attenuated or enhanced the HagB-induced MMP2 and MMP12 responses ( Figures 3B and 3E ). HBD3 treatment alone (Group 3, Group5) induced some MMP production, but this response was less than the MMP production induced by HagB treatment. These results suggest that HBD3 has the potential to regulate the production of MMPs from dendritic cells exposed to a proinflammatory stimulus. To what extent this mechanism occurs with other cells that are capable of expressing MMPs, 5, 6 such as gingival sulcular epithelial cells, gingival fibroblasts, endothelial cells, monocytes, macrophages, plasma cells, neoplastic cells, and PMN leukocytes, is not yet known. Because MMPs also play critical roles in immune responses by either modifying proteins posttranslationally to promote rapid delivery to other cells or by inactivating these proteins to initiate or terminate the immune process, 4 inhibition of their production by a proinflammatory stimulus would dampen the roles of MMPs in local and systematic inflammation and regulate cytokine biosynthesis through activation of signal transduction pathways. Again, a better understanding of the biochemical and regulatory pathways of these proteins will assist in identifying ways to target MMPs with a goal to arrest or attenuate the progression of inflammation and tissue damage in periodontal disease.
Both HBD3 and HagB are associated with the MyD88 and TRIF pathways, which when activated can lead to downstream MMP production. With the predicted pathways proposed in this study, we suspect the inhibition of CD14 by HBD3, decreasing the amount of HagB able to bind to CD14, resulted in decreased MMP production in the groups treated with HBD3 and HagB. This prediction needs to be further tested using pathway inhibitors. Another possibility, which has been explored in some of the author group's previous work, 10 is that multiple pathways are involved simultaneously. We have seen that in the presence of HagB, low amounts of HBD3 can cause a slightly enhanced MMP7 production (Group 4), while higher amounts of HBD3 can attenuate MMP7 production (Group 6). In reference to Figure 4 , with HagB and lower amounts of HBD3 present, multiple pathways (both right and left sides of Figure 4 ) might be activated, while with HagB and higher amounts of HBD3 present, the HBD3 might inhibit certain pathways (left side of Figure 4 ) downstream of HagB causing less MMP production. Again, this prediction needs to be further tested using pathway inhibitors.
CONCLUSION
In this study, 2.0 m HagB was found to be an MMP stimulus and HBD3 was found to decrease the HagB-induced MMP1, -7, and -9 responses in dendritic cells at 16 hours, an observation that suggests HBD3 can alter microbial antigen-induced production of MMPs.
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